Since such fibrosis is fundamental to the impairment of cardiac distensibility and glomerular function that characterizes obesity-related HFpEF, SGLT2 inhibitors can contribute to reduced perivisceral, perivascular, and pericardial adipose tissue deposition and inflammation. Here, SLC5A2 is linked to obesity disorder.